The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease.
On-the-job exposure to electromagnetic fields may double the risk of developing amyotrophic lateral sclerosis (ALS), a degenerative disease of the nervous system, a new study suggests.